Estrategias de Reperfusión en el tratamiento de la embolia pulmonar aguda: Una revisión narrativa de la literatura

Reperfusion strategies in acute pulmonary embolism: A narrative review

Publicado 2023-06-01

Abrir | Descargar
PDF FLIP
Número
Vol. 35 Núm. 1 (2023): .
Sección
Revisión de tema
Cómo citar
Estrategias de Reperfusión en el tratamiento de la embolia pulmonar aguda: Una revisión narrativa de la literatura.
rev. colomb. neumol. [Internet]. 2023 Jun. 1 [cited 2024 Dec. 26];35(1):34-45. Disponible en: https://doi.org/10.30789/rcneumologia.v35.n1.2023.603
DOI

https://doi.org/10.30789/rcneumologia.v35.n1.2023.603
Dimensions
PlumX
Licencia
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Alvaro Zarama Valenzuela
Hospital Universitario San Ignacio image/svg+xml
    https://orcid.org/0000-0002-0301-5545
    Carlos Andrés Celis-Preciado
    Pontificia Universidad Javeriana image/svg+xml
      https://orcid.org/0000-0001-8405-4513
      Claudio Villaquirán-Torres
      Hospital Universitario San Ignacio image/svg+xml
        https://orcid.org/0000-0002-3743-6268
        Mostrar biografía de los autores

        La embolia pulmonar (EP) es una patología con gran carga de morbimortalidad, que amerita un diagnóstico y tratamiento oportunos, para mejorar los desenlaces de los pacientes. En el escenario agudo la trombólisis, bien sea por vía sistémica o dirigida por catéter, constituye una de las opciones de tratamiento que debe ser considerada. En este artículo se revisa la evidencia existente con respecto a las indicaciones de la terapia trombolítica, su eficacia y riesgos asociados.

        Visitas del artículo 497 | Visitas PDF 653

        Descargas

        Los datos de descarga todavía no están disponibles.
        1. Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013;18(2):129–38. PMID: 23940438; PMCID: PMC3718593.
        2. Dennis R, De Arboleda MN, Rodriguez MN, Salazar MS, Posada PS. Estudio nacional sobre tromboembolismo venoso en población hospitalaria en Colombia: Diferencias entre ciudades y especialidades. Acta Médica Colomb. 1996;21(2):55–63. ID: lil-183342.
        3. Dennis R, Rojas MX, Molina Á, Roa J, Granados M, Londoño A, et al. Curso clínico y supervivencia en embolia pulmonar: Resultados del registro multicéntrico colombiano (EMEPCO). Acta Medica Colomb. 2008;33(3):111–6. ISSN 0120-2448.
        4. Yamamoto T. Management of patients with high-risk pulmonary embolism: a narrative review. J Intensive Care. 2018;6:16. doi: 10.1186/s40560-018-0286-8.
        5. Thabut G, Thabut D, Myers RP, Bernard-Chabert B, Marrash-Chahla R, Mal H, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol. 2002;40(9):1660–7. doi: 10.1016/s0735-1097(02)02381-1.
        6. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials. Circulation. 2004;110(6):744–9. doi: 10.1161/01.CIR.0000137826.09715.9C.
        7. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. N Engl J Med. 2014;370(15):1402–11. doi: 10.1056/NEJMoa1302097.
        8. Goldhaber SZ. PEITHO Long-Term Outcomes Study. J Am Coll Cardiol. 2017;69(12):1545–8. doi: 10.1016/j.jacc.2017.01.027.
        9. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage. JAMA. 2014;311(23):2414. doi: 10.1001/jama.2014.5990.
        10. Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015;36(10):605–14. doi: 10.1093/eurheartj/ehu218.
        11. Zuo Z, Yue J, Dong BR, Wu T, Liu GJ, Hao Q. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2021;4(4):CD004437. doi: 10.1002/14651858.CD004437.pub6.
        12. Izcovich A, Criniti JM, Popoff F, Lu L, Wu J, Ageno W et al. Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. Blood Adv. 2020;4(7):1539-1553. doi: 10.1182/bloodadvances.2020001513.
        13. Hao Q, Dong BR, Yue J, Wu T, Liu GJ. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2015;(9):CD004437. doi: 10.1002/14651858.CD004437.pub4.
        14. Xu Q, Huang K, Zhai Z, Yang Y, Wang J, Wang C. Initial thrombolysis treatment compared with anticoagulation for acute intermediate-risk pulmonary embolism: a meta-analysis. J Thorac Dis. 2015;7(5):810–21. doi: 10.3978/j.issn.2072-1439.2015.04.51.
        15. Gao G, Yang P, Liu M, Ding M, Liu G, Tong Y, et al. Thrombolysis for acute intermediate-risk pulmonary embolism: A meta-analysis. Thromb Res. 2015;136(5):932–7. doi: 10.1016/j.thromres.2015.09.012.
        16. Cao J, Cao Y, Chen H, Gao W, Wang Y. Systematic review and meta-analysis for thrombolysis treatment in patients with acute submassive pulmonary embolism. Patient Prefer Adherence. 2014;8:275. doi: 10.2147/PPA.S56280.
        17. Liu Y, Lu Y, Song J, Li D, Liu H, Yang J, et al. Recombinant tissue plasminogen activator for hemodynamically stable patients experiencing an acute pulmonary embolism: A meta-analysis. Thromb Res. 2014;134(1):50–6. doi: 10.1016/j.thromres.2014.04.007.
        18. Nakamura S, Takano H, Kubota Y, Asai K, Shimizu W. Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a meta-analysis. J Thromb Haemost. 2014;12(7):1086–95. doi: 10.1111/jth.12608.
        19. Riera-Mestre A, Becattini C, Giustozzi M, Agnelli G. Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: A meta-analysis. Thromb Res. 2014;134(6):1265–71. doi: 10.1016/j.thromres.2014.10.004.
        20. Zhang Z, Zhai Z, Liang L, Liu F, Yang Y, Wang C. Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: A systematic review and meta-analysis. Thromb Res. 2014;133(3):357–63. doi: 10.1016/j.thromres.2013.12.026.
        21. Chen H, Ren C, Chen H. Thrombolysis Versus Anticoagulation for the Initial Treatment of Moderate Pulmonary Embolism: A Meta-Analysis of Randomized Controlled Trials. Respir Care. 2014;59(12):1880–7. doi: 10.4187/respcare.03197.
        22. Wang T-F, Squizzato A, Dentali F, Ageno W. The role of thrombolytic therapy in pulmonary embolism. Blood. 2015;125(14):2191–9. doi: 10.1182/blood-2014-08-559278.
        23. Naidu SG, Knuttinen M-G, Kriegshauser JS, Eversman WG, Oklu R. Rationale for catheter directed therapy in pulmonary embolism. Cardiovasc Diagn Ther. 2017;7(Suppl 3):S320–8. doi: 10.21037/cdt.2017.08.14.
        24. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P et al. 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. doi: 10.1093/eurheartj/ehz405.
        25. Fiumara K, Kucher N, Fanikos J, Goldhaber SZ. Predictors of Major Hemorrhage Following Fibrinolysis for Acute Pulmonary Embolism. Am J Cardiol. 2006;97(1):127–9. doi: 10.1016/j.amjcard.2005.07.117.
        26. Chatterjee S, Weinberg I, Yeh RW, Chakraborty A, Sardar P, Weinberg MD, et al. Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. Thromb Haemost. 2017;117(02):246–51. doi: 10.1160/TH16-07-0588.
        27. Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol. 1997;80(2):184–8. doi: 10.1016/s0002-9149(97)00315-9.
        28. Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, et al. Efficacy and Safety of Low Dose Recombinant Tissue-Type Plasminogen Activator for the Treatment of Acute Pulmonary Thromboembolism. Chest. 2010;137(2):254–62. doi: 10.1378/chest.09-0765.
        29. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate Pulmonary Embolism Treated With Thrombolysis (from the “MOPETT” Trial). Am J Cardiol. Excerpta Medica. 2013;111(2):273–7. doi: 10.1016/j.amjcard.2012.09.027.
        30. Sanchez O, Charles-Nelson A, Ageno W, Barco S, Binder H, Chatellier G et al. Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-Risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thromb Haemost. 2022;122(5):857-866.
        31. Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann L V. Catheter-directed Therapy for the Treatment of Massive Pulmonary Embolism: Systematic Review and Meta-analysis of Modern Techniques. J Vasc Interv Radiol. 2009;20(11):1431–40. doi: 10.1016/j.jvir.2009.08.002.
        32. Avgerinos ED, Saadeddin Z, Abou Ali AN, Fish L, Toma C, Chaer M, et al. A meta-analysis of outcomes of catheter-directed thrombolysis for high- and intermediate-risk pulmonary embolism. J Vasc Surg Venous Lymphat Disord. 2018;6(4):530–40. doi: 10.1016/j.jvsv.2018.03.010.
        33. Kaymaz C, Akbal OY, Tanboga IH, Hakgor A, Yilmaz F, Ozturk S et al. Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: A Meta-Analysis. Curr Vasc Pharmacol. 2018;16(2):179-189. doi: 10.2174/1570161115666170404122535.
        34. Pei DT, Liu J, Yaqoob M, Ahmad W, Bandeali SS, Hamzeh IR et al. Meta-analysis of Catheter Directed Ultrasound-Assisted Thrombolysis in Pulmonary Embolism. Am J Cardiol. 2019;124(9):1470-1477. doi: 10.1016/j.amjcard.2019.07.040.
        35. Wu J, Chen H, Yu Y, Peng L, Li J, Liang H et al. Feasability of ultrasound-assisted catheter-directed thrombolysis for submassive pulmonary embolism: A meta-analysis of case series. Clin Respir J. 2020;14(5):430-439. doi: 10.1111/crj.13155.
        36. EKOS Corporation. EkoSonic MACH4 Endovascular Device Instructions for Use. EKOS corporation [s.f.]. Disponible en: https://www.btg-im.com/BTG/media/EKOS-Files/EKOS%20Instructions%20For%20Use/6998_B_IFU-EkoSonic-MACH4-PE-Peripheral.pdf
        37. Aggarwal V, Nicolais CD, Lee A, Bashir R. Acute Management of Pulmonary Embolism (Internet). American College of Cardiology. 2017. Disponible en: https://www.acc.org/latest-in-cardiology/articles/2017/10/23/12/12/acute-management-of-pulmonary-embolism.
        38. Piazza G, Goldhaber SZ. Management of submassive pulmonary embolism. Circulation. 2010;122(11):1124–9. doi: 10.1161/CIRCULATIONAHA.110.961136
        39. Jimenez D, Martin-Saborido C, Muriel A, Zamora J, Morillo R, Barrios D, et al. Efficacy and safety outcomes of recanalisation procedures in patients with acute symptomatic pulmonary embolism: systematic review and network meta-analysis. Thorax. 2018;73:464-471. doi: 10.1136/thoraxjnl-2017-210040.
        40. Pasha AK, Siddiqui MU, Siddiqui MD, Ahmed A, Abdullah A, Riaz I et al. Catheter directed compared to systematically delivered thrombolysis for pulmonary embolus: a systematic review and meta-analysis. J Thromb Thrombolysis. 2021;53:454-466. doi: 10.1007/s11239-021-02556-7.
        41. Siordia JA, Kaur A. Catheter-Directed Thrombolysis versus Systemic Anticoagulation for Submassive Pulmonary Embolism: A Meta-Analysis. Curr Cardiol Rev. 2021;18(1):112-117. doi: 10.2174/1573403X17666210603114116.
        42. Avgerinos ED, Jaber W, Lacomis J, Markel J, McDaniel M, Rivera-Lebron BN et al. Randomized Trial Comparing Standard Versus Ultrasound Thrombolysis for Submassive Pulmonary Embolism. JACC Cardiovasc Interv. 2021;14(12):1364-1373. doi: 10.1016/j.jcin.2021.04.049.
        43. Dudzinski DM, Piazza G. Multidisciplinary Pulmonary Embolism Response Teams. Circulation. 2016;133(1):98–103. doi: 10.1161/CIRCULATIONAHA.115.015086.
        44. Rodriguez-Lopez J, Channick R. The Pulmonary Embolism Response Team: What Is the Ideal Model? Semin Respir Crit Care Med. 2017;38(01):051–5. doi: 10.1055/s-0036-1597561.
        Tutoriales

        Autores:

        ¿Cómo enviar un artículo?

        Par evaluador:

        ¿Cómo evaluar un artículo?

        Información

        Historia de la revista

        Palabras clave

        Directorios e indexadores

         

        Patrocinadores

         Nos apoyan + Info Aquí 

        Perfil de Google Scholar

        Más leídos en los últimos 30 días

        Número actual

        Código QR

        Sistema OJS 3.4.0.7 - Metabiblioteca |